Core Insights - The new campus of Guangming District People's Hospital is expected to begin trial operations by the end of this year, with a total construction area of approximately 340,000 square meters and the capacity to provide 1,500 beds [1] - The hospital aims to enhance the region's emergency and critical care capabilities and contribute to the establishment of an integrated health ecosystem in Guangming Science City [1][2] Group 1 - The new hospital campus is a significant milestone for Guangming District People's Hospital, which has evolved from two rudimentary health posts in 1952 to a comprehensive hospital with over 50 community health centers and an annual patient volume exceeding 4.5 million [1][2] - The hospital has achieved several milestones, including recognition as a national-level chest pain center and heart failure center, and has maintained an A-level quality in medical data [2] - The hospital's innovative "1234" scientific and educational integration system includes the establishment of one national drug trial base, two translational research bases, three scientific and educational platforms, and four talent training bases [2] Group 2 - The opening of the new campus and collaboration with Shenzhen University of Technology will focus on building five critical care centers and seven academic clusters, aiming for breakthroughs in key disciplines at the municipal level [2]

"本次创新场景发布，不是一场简单的供需对接会或招商推介会，而是围绕各类场景，开放成都未来医 学城在产业发展、科技创新、成果转化、生态建设、公服配套等领域的多元化应用测试环境，以项目化 思维帮助园区企业获得订单，帮助区外企业拓展市场，助力医学城链接资源、扩大行业影响，最终实现 合作共赢。"成都未来医学城管理局相关负责人表示。 7月5日，第42届全国医药工业信息年会和2025北京·昌平生命科学论坛开幕，开幕式上发布了《2025年 中国特色生物医药产业园区优秀案例》榜单。来自成都东部新区的成都未来医学城凭借在"医教研产"一 体化创新转化体系方面的突破性实践，与北上深等地的8个知名产业园区共同入选，并被授予"未来医学 创新转化典范"称号。这标志着成都东部新区、未来医学城在科技创新与成果转化实践中获得"国家 级"认可。 "未来医学城深刻分析当前生物产业发展中临床需求与供给侧脱节和园区对企业创新策源能力不足两大 痛点。创新实践'医教研产'以临床需求出发的生命健康产业发展新模式。为全国生物医药产业园区转型 升级和创新发展提供了极具价值的'成都样本'与'四川经验'。这也是该园区获得'未来医学创新转化典 范'称号的重要原因之一 ...

Core Viewpoint - The collaboration between Guangdong Pharmaceutical University and Foshan Second People's Hospital aims to establish a high-level hospital and clinical medical college, enhancing healthcare quality and talent development in the region [1][2]. Group 1: Collaboration Agreement - A cooperation agreement was signed to build a new type of affiliated hospital and clinical medical college, focusing on resource sharing and mutual development [1]. - The agreement includes a commitment to invest in clinical specialties and aims to achieve breakthroughs in national and provincial clinical key specialties [1]. Group 2: Talent Development - The partnership will leverage the strengths of Guangdong Pharmaceutical University in clinical medicine and nursing to cultivate high-quality medical talent through specialized programs [1]. - Initiatives such as the "3+2" program and new undergraduate majors will be introduced to support the hospital's academic needs [1]. Group 3: Research Collaboration - The collaboration will utilize the university's research capabilities to address clinical issues, fostering a robust research system within the hospital [1]. - Joint research efforts will be established to produce continuous scientific outcomes, supporting the integrated development of medical education and research [1]. Group 4: Future Development and Innovation - The partnership is seen as a strategic move to enhance both institutions' development and contribute to regional health initiatives [2]. - The focus will be on innovative hospital management and collaborative development mechanisms to improve healthcare delivery and expand influence beyond local services [2]. Group 5: Inauguration of Collaborative Bases - The signing event included the inauguration of several collaborative bases, such as the Third Clinical Medical College and Graduate Training Base of Guangdong Pharmaceutical University [2]. Group 6: Management Capacity Building - A report on modern hospital management was presented, emphasizing the importance of management strategies for high-quality hospital development [3].